Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 7, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-10-13
DOI
10.3389/fphar.2016.00376
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
- (2016) Pasquale Rescigno et al. EUROPEAN UROLOGY
- Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
- (2016) David Lorente et al. EUROPEAN UROLOGY
- Prostate cancer
- (2016) Gerhardt Attard et al. LANCET
- Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
- (2016) Alessandro Passardi et al. Oncotarget
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
- (2016) Cristian Lolli et al. Oncotarget
- Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer
- (2016) M Mego et al. Journal of Cancer
- Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer
- (2016) Vincenza Conteduca et al. PLoS One
- Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
- (2015) S Salvi et al. BRITISH JOURNAL OF CANCER
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients
- (2015) Vincenza Conteduca et al. Future Oncology
- Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer
- (2015) Nathan A. Cannon et al. Journal of Thoracic Oncology
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
- (2014) R. Leibowitz-Amit et al. ANNALS OF ONCOLOGY
- Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
- (2014) D. Lorente et al. ANNALS OF ONCOLOGY
- High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer
- (2014) Lorena Rossi et al. ANNALS OF SURGICAL ONCOLOGY
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
- (2014) B. Hu et al. CLINICAL CANCER RESEARCH
- Neuroendocrine differentiation in prostate cancer: Current and emerging therapy strategies
- (2014) Vincenza Conteduca et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone
- (2014) Salvatore Luca Burgio et al. ENDOCRINE-RELATED CANCER
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel
- (2013) Philipp Nuhn et al. BJU INTERNATIONAL
- Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment
- (2013) W Nathaniel Brennen et al. ENDOCRINE-RELATED CANCER
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer
- (2012) Ugo De Giorgi et al. Clinical Breast Cancer
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes in Biomarkers of Inflammation and Angiogenesis During Androgen Deprivation Therapy for Prostate Cancer
- (2012) P. J. Saylor et al. ONCOLOGIST
- Re: Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-Label Trial
- (2011) Philippe Beuzeboc EUROPEAN UROLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search